Across TCGA pan-cancer cohorts, RNA5SP335 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RNA5SP335’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RNA5SP335 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNA5SP335 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.
LIHC, STAD, and KIRC are the cancer types where RNA5SP335 tumor–normal differential expression is most reproducible.